PMID- 38113872 OWN - NLM STAT- MEDLINE DCOM- 20240408 LR - 20240408 IS - 1423-0194 (Electronic) IS - 0028-3835 (Linking) VI - 114 IP - 4 DP - 2024 TI - The Reduced Gray Matter Volume and Functional Connectivity of the Cerebellum in Type 2 Diabetes Mellitus with High Insulin Resistance. PG - 386-399 LID - 10.1159/000535860 [doi] AB - INTRODUCTION: Insulin resistance is widely thought to be a critical feature in type 2 diabetes mellitus (T2DM), and there is significant evidence indicating a higher abundance of insulin receptors in the human cerebellum than cerebrum. However, the specific structural or functional changes in the cerebellum related to T2DM remain unclear, and the association between cerebellar alterations, insulin resistance, cognition, and emotion is yet to be determined. METHODS: We investigated neuropsychological performance, and structural and functional changes in specific cerebellar subregions in 43 T2DM patients with high insulin resistance (T2DM-highIR), 72 T2DM patients with low insulin resistance (T2DM-lowIR), and 50 controls. Furthermore, the correlation and stepwise multiple linear regression analysis were performed. RESULTS: Compared to the controls, T2DM exhibited lower cognitive scores and higher depressive/anxious scores. Furthermore, T2DM-highIR patients showed reduced gray matter volume (GMV) in the right cerebellar lobules VIIb, Crus I/II, and T2DM showed reduced GMV in left lobules I-IV compared to controls. Additionally, functional connectivity decrease was observed between the right lobules I-V and orbital part of the superior frontal gyrus in T2DM-highIR compared to both T2DM-lowIR and controls. Notably, there were negative correlations between the GMV of the lobules VIIb, Crus I/II, and updated homeostatic model assessment of insulin resistance, and positive correlation with executive/visuospatial performance in T2DM patients. CONCLUSIONS: These results suggest that the cerebellar lobules VIIb, Crus I/II, represent vulnerable brain regions in the context of insulin resistance. Overall, this study offers new insights into the neuropathophysiological mechanisms of brain impairment in patients with T2DM. CI - (c) 2023 S. Karger AG, Basel. FAU - Zhang, Hui-Yan AU - Zhang HY AD - School of Clinical Medicine, Ningxia Medical University, Yinchuan, China. AD - Department of Radiology, Gansu Provincial Hospital, Lanzhou, China. FAU - Shen, Guo AU - Shen G AD - School of Clinical Medicine, Ningxia Medical University, Yinchuan, China. AD - Department of Radiology, Gansu Provincial Hospital, Lanzhou, China. FAU - Yang, Chen AU - Yang C AD - Department of Radiology, Gansu Provincial Hospital, Lanzhou, China. AD - The First Clinical Medical College of Gansu University of Chinese Medicine (Gansu Provincial Hospital), Lanzhou, China. FAU - Tan, Jian AU - Tan J AD - Department of Radiology, Gansu Provincial Hospital, Lanzhou, China. AD - The First Clinical Medical College of Gansu University of Chinese Medicine (Gansu Provincial Hospital), Lanzhou, China. FAU - Cao, Jian-Cang AU - Cao JC AD - Department of Radiology, Gansu Provincial Hospital, Lanzhou, China. FAU - Tian, Jing AU - Tian J AD - Department of Radiology, Gansu Provincial Hospital, Lanzhou, China. FAU - Li, Zhou-Le AU - Li ZL AD - The First Clinical Medical College of Gansu University of Chinese Medicine (Gansu Provincial Hospital), Lanzhou, China. FAU - Huang, Gang AU - Huang G AD - Department of Radiology, Gansu Provincial Hospital, Lanzhou, China. FAU - Zhao, Lian-Ping AU - Zhao LP AD - Department of Radiology, Gansu Provincial Hospital, Lanzhou, China. LA - eng PT - Journal Article DEP - 20231219 PL - Switzerland TA - Neuroendocrinology JT - Neuroendocrinology JID - 0035665 SB - IM MH - Humans MH - Gray Matter/diagnostic imaging MH - *Insulin Resistance MH - *Diabetes Mellitus, Type 2 MH - Magnetic Resonance Imaging/methods MH - Cerebellum/diagnostic imaging MH - *Hyperinsulinism OTO - NOTNLM OT - Cerebellum OT - Diabetes mellitus OT - Insulin resistance OT - Magnetic resonance imaging OT - Structure and function OT - Type 2 EDAT- 2023/12/19 19:55 MHDA- 2024/04/08 06:42 CRDT- 2023/12/19 18:26 PHST- 2023/09/15 00:00 [received] PHST- 2023/12/14 00:00 [accepted] PHST- 2024/04/08 06:42 [medline] PHST- 2023/12/19 19:55 [pubmed] PHST- 2023/12/19 18:26 [entrez] AID - 000535860 [pii] AID - 10.1159/000535860 [doi] PST - ppublish SO - Neuroendocrinology. 2024;114(4):386-399. doi: 10.1159/000535860. Epub 2023 Dec 19.